Leap Therapeutics Q1 2021 Earnings Report
Key Takeaways
Leap Therapeutics reported a net loss of $9.1 million for the first quarter of 2021, compared to a net loss of $7.2 million for the same period in 2020. License revenues were $0.4 million for both the first quarter of 2021 and 2020.
Net loss was $9.1 million for the first quarter 2021, compared to $7.2 million for the same period in 2020.
License revenues were $0.4 million for each of the first quarter 2021 and 2020.
Research and development expenses were $6.8 million for the first quarter 2021, compared to $4.6 million for the same period in 2020.
Cash and cash equivalents totaled $43.5 million at March 31, 2021.
Leap Therapeutics
Leap Therapeutics
Forward Guidance
This press release contains forward-looking statements within the meaning of the securities act of 1933 and the securities exchange act of 1934, which involve risks and uncertainties.